| # | Title | Journal | Year | Citations |
|---|
| 1 | Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer | New England Journal of Medicine | 2015 | 7,261 |
| 2 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | New England Journal of Medicine | 2015 | 6,773 |
| 3 | Nivolumab plus Ipilimumab in Advanced Melanoma | New England Journal of Medicine | 2013 | 3,776 |
| 4 | Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial | Lancet, The | 2017 | 3,224 |
| 5 | Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial | Lancet Oncology, The | 2015 | 2,353 |
| 6 | Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study | Lancet Oncology, The | 2017 | 2,058 |
| 7 | Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial | Lancet, The | 1999 | 1,938 |
| 8 | Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma | New England Journal of Medicine | 2012 | 1,836 |
| 9 | Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens | Nature | 2014 | 1,705 |
| 10 | Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab | Cell | 2017 | 1,515 |
| 11 | Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial | Lancet Oncology, The | 2017 | 1,388 |
| 12 | Applications of machine learning in drug discovery and development | Nature Reviews Drug Discovery | 2019 | 1,358 |
| 13 | Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial | Lancet Oncology, The | 2014 | 1,280 |
| 14 | Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial | Lancet Oncology, The | 2015 | 1,269 |
| 15 | The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis | Journal of Hepatology | 2019 | 1,253 |
| 16 | Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study | Lancet, The | 2020 | 1,224 |
| 17 | Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy | New England Journal of Medicine | 2016 | 1,140 |
| 18 | Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma | New England Journal of Medicine | 2015 | 1,139 |
| 19 | Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts | Cancer Discovery | 2019 | 1,120 |
| 20 | Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial | Lancet Oncology, The | 2015 | 1,093 |
| 21 | Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial | Lancet Oncology, The | 2016 | 1,091 |
| 22 | Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial | Lancet Oncology, The | 2018 | 1,089 |
| 23 | Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U.S. Adult Population | American Journal of Cardiology | 2013 | 1,032 |
| 24 | Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial | Lancet Oncology, The | 2012 | 995 |
| 25 | Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma | Science | 2018 | 898 |
| 26 | AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation | Proceedings of the National Academy of Sciences of the United States of America | 2002 | 895 |
| 27 | Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study | Lancet Oncology, The | 2017 | 845 |
| 28 | A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study) | American Journal of Transplantation | 2010 | 838 |
| 29 | Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial | Lancet Oncology, The | 2016 | 827 |
| 30 | Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial | Lancet Oncology, The | 2016 | 818 |
| 31 | Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study | Liver International | 2015 | 813 |
| 32 | Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma | JAMA Oncology | 2020 | 805 |
| 33 | Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial | Lancet Oncology, The | 2019 | 767 |
| 34 | Neuropsychiatric symptoms in Alzheimer's disease | Alzheimer's and Dementia | 2011 | 752 |
| 35 | Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial | Lancet, The | 2010 | 751 |
| 36 | Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer | Cancer Cell | 2018 | 725 |
| 37 | Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia | Science | 1992 | 716 |
| 38 | Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement | Pharmaceutical Research | 2006 | 684 |
| 39 | Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts | Breast Cancer Research | 2005 | 659 |
| 40 | A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer | JAMA Oncology | 2017 | 658 |
| 41 | Hepatotoxicity with Combination of Vemurafenib and Ipilimumab | New England Journal of Medicine | 2013 | 655 |
| 42 | Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise | Diabetes Care | 2010 | 628 |
| 43 | Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate | Annals of the Rheumatic Diseases | 2009 | 604 |
| 44 | Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes | Diabetes Care | 2009 | 604 |
| 45 | Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial | Lancet Oncology, The | 2016 | 594 |
| 46 | Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial | Lancet Oncology, The | 2019 | 594 |
| 47 | Belatacept and Long-Term Outcomes in Kidney Transplantation | New England Journal of Medicine | 2016 | 593 |
| 48 | Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression | Oral Oncology | 2018 | 589 |
| 49 | A general alkyl-alkyl cross-coupling enabled by redox-active esters and alkylzinc reagents | Science | 2016 | 579 |
| 50 | Discovery and Preclinical Profile of Saxagliptin (BMS-477118): A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes | Journal of Medicinal Chemistry | 2005 | 577 |
